{'fraction_non_alphanumeric': 0.024853801169590642, 'fraction_numerical': 0.011695906432748537, 'mean_word_length': 5.284403669724771, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Intravenous Iron Isomaltoside for Patients With Iron Deficiency Undergoing Elective Surgery


The results of 1 randomized controlled trial did not find a difference in functional status (6-minute walk distance and New York Heart Association class), hand grip strength, or health-related quality of life for patients who underwent a transcatheter aortic valve implantation treated with iron isomaltoside versus placebo. 
There was 1 (1.4%) hypersensitivity reaction and 1 (1.4%) episode of chest pain in patients treated with iron isomaltoside in the randomized controlled trial. Rates of other adverse events were similar between patients treated with iron isomaltoside and placebo. 
